<unk>  (INN; brand name Polivy, is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved<unk>  in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab. The drug was developed by Genentech and Roche.
Polatuzumab vedotin
Loncastuximab tesirine
Ponatinib
Neratinib
Dasatinib
Tucatinib
Imatinib
Lapatinib